As of last Friday, pharma and biotech companies had disclosed 16 breakthrough therapy designations, half of them for cancer indications. FDA does not disclose what products have been applied for or received the designation. As of June 14, the Center for Drug Evaluation and Research (CDER) had received 56 breakthrough designation requests, had granted 20 and denied 15. As of May 31, the Center for Biologics Evaluation and Research (CBER) had received 6 designation requests, denied 5 and